Open AccessNew therapy options for patients with eosinophilic type of severe bronchial asthma
Author(s) -
Г. Л. Игнатова,
В. Н. Антонов,
Е В Блинова,
Irina Grebneva,
E. V. Sheklanova
Publication year - 2020
Publication title -
medicinskij sovet
Language(s) - English
Resource type - Journals
eISSN - 2658-5790
pISSN - 2079-701X
DOI - 10.21518/2079-701x-2019-21-111-116
Subject(s) - endotype , benralizumab , medicine , asthma , mepolizumab , eosinophilic , referral , medical prescription , intensive care medicine , pulmonology , epidemiology , pulmonologist , pathology , eosinophil , family medicine , pharmacology
The article provides data on the epidemiology of severe asthma. It defines the phenotype and endotype of bronchial asthma and classifies BA according to phenotype/endotype. The features of the eosinophilic phenotype of severe bronchial asthma are considered. Clinical characteristics of the patient corresponding to the prescription of benralizumab are presented. The algorithm of decision making by a doctor-therapist about patients’ referral to a pulmonologist for consideration of the biological therapy issue is given. The results of the main clinical studies to assess the efficacy and safety of benralizumab in patients with severe eosinophilic bronchial asthma: SIROCCO, CALIMA, ZONDA, BORA are described. The experience of using various biological preparations for the treatment of severe asthma in Chelyabinsk and the Chelyabinsk Region has also been summarized.